References
- Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410-6.
- Savoia P, Astrua C, Fava P. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: effectiveness and toxicity management. Hum Vaccin Immunother. 2016;12(5):1092-101.
- Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-74.
- Liu M, Yuan M, Sun W, Li Z, Zhou X, Wang C. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid. Invest New Drugs. 2023;41(6):802-7.
- Anastasopoulou A, Papaxoinis G, Diamantopoulos P, Christofidou E, Benopoulou O, Stratigos A, et al. Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivo lumab: case report and review of the literature. J Immu nother. 2018; 41(3):164-7.
- Mazumder A, Darji K, Smith K, Guo M. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors. BMJ Case Rep. 2022;15(12):e253059.
- Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133-46.
- Holtsche MM, Boch K, Schmidt E. Autoimmune bullous dermatoses. J Dtsch Dermatol Ges. 2023; 21(4):405-12.
- U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0 [Internet]. 2017 [cited 2025 Jun 5]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pd
- Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36 (10) :1689-704.
- Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist. 2018;23(10):1119-26.
- Olsen E, Svoboda SA, Saikaly SK, Missall TA, Motaparthi K. Delayed onset of bullous pemphigoid secondary to nivolumab. Cureus. 2023;15(8):e43230.
- Hansen I, Gebhardt C, Booken N, Schneider SW. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma. JDDG - Journal of the German Society of Dermatology. 2024;22(4):587-9.
- Merli M, Accorinti M, Romagnuolo M, Marzano A, Di Zenzo G, Moro F, et al. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med (Lausanne). 2023;10:1208418.
- Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018; 57-(6):664-9.
- Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, et al. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermato-logic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer. 2024;12 (4):e007675.
- Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28(12):6119-28.
- Wang M, Wang J, Shi B. Case report: dupilumab for the treatment of bullous pemphigoid. Dermatol Ther. 2022;35(7):e15541.
- Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol Online J. 2019;25(11):13030/qt25q9w6r9.
- Kuo AM, Gu S, Stoll J, Moy AP, Dusza SW, Gordon A, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023;11(6):e007324.